Advertisement

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group.

 Practice Update

click me